Aspirin,
does it really help with Reduced early vascular mortality in acute myocardial infarction?
research showsAspirin given early under medical direction for suspected acute myocardial infarction is rated A because it directly reduces vascular mortality from randomization through day 35. ISIS-2 randomized and analyzed all 17,187 participants as allocated. In the aspirin comparison, vascular death occurred in 804 of 8,587 patients (9.4%) versus 1,016 of 8,600 (11.8%), meeting the protocol-prespecified primary analysis endpoint with 2P<0.00001. This was a large hard-outcome trial with an absolute reduction of 2.4 percentage points, and nonfatal reinfarction and stroke also decreased.
ads claimMarketing and popular advice can simplify aspirin into a daily heart supplement for everyone. The demonstrated use here is early antiplatelet treatment during suspected acute myocardial infarction, not unsupervised primary prevention or self-treatment before the cause of chest pain is assessed.
Useful facts when choosing a product
- ISIS-2 used aspirin 160 mg daily for one month, with the first dose administered within an acute myocardial infarction care protocol.
- Enteric-coated tablets may absorb more slowly than promptly absorbed formulations, so local emergency guidance and professional direction take priority.
- Aspirin allergy, active bleeding, selected bleeding disorders, and concurrent anticoagulation require immediate clinical assessment.
- Chest pain warrants prompt contact with emergency services rather than delaying care to locate medication; this verdict is not an individualized dosing instruction.
What the research actually shows
ISIS-2 randomized 17,187 patients with suspected acute myocardial infarction within 24 hours of symptom onset in a 2-by-2 factorial comparison of streptokinase and aspirin. In the one-month aspirin 160-mg daily comparison, the protocol-prespecified primary analysis endpoint was vascular mortality from randomization through day 35; it fell from 1,016 of 8,600 to 804 of 8,587, with 2P<0.00001. Nonfatal reinfarction was 1.0% versus 2.0%, and nonfatal stroke was 0.3% versus 0.6%. From day 36 through ten years, the mortality rate ratio was 0.99 (95% CI 0.93 to 1.06), so there was no additional benefit, while the early survival advantage was maintained. Behringwerke/Hoechst provided the main industry funding and the British Heart Foundation supported coordination.
Why this is classified as A (94)
An all-randomized analysis of 17,187 participants reduced the protocol-prespecified day 0-to-35 vascular-mortality endpoint from 11.8% to 9.4%, with 2P<0.00001. There was no additional mortality benefit from day 36 to ten years, but the early survival advantage persisted. A single pivotal industry-funded trial does not receive the corpus maximum, while rule ②-b does not cap this exceptionally large prescription-drug hard-outcome trial, supporting A with 94 points.
Counterpoint. The strong benefit in acute myocardial infarction does not automatically extend to primary prevention in healthy people. Bleeding risk and contraindications still require medically directed use.
Rejudgment record. Cross-check applied — The day 0-to-35 vascular-mortality primary endpoint succeeded among all 17,187 randomized patients, the early benefit persisted without additional benefit from day 36 to ten years, and a single pivotal industry-funded trial does not receive the corpus maximum.
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Reduced five-week vascular mortality in acute myocardial infarction | A | The direct mortality endpoint succeeded in the analysis of all 17,187 randomized patients. |
| Reduced nonfatal reinfarction in acute myocardial infarction | A | ISIS-2 reduced the outcome from 2.0% to 1.0%. |
| Reduced nonfatal stroke in acute myocardial infarction | B | The direct signal was positive at 0.3% versus 0.6%, although event counts were smaller than for mortality. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| ISIS-2 Collaborative Group. 1988 | Multicenter randomized double-blind placebo-controlled 2-by-2 factorial trial | 8,600 | Mainly industry funded by Behringwerke/Hoechst, with coordination supported by the British Heart Foundation and aspirin and placebo donated by Sterling Drugs | Protocol-prespecified primary analysis endpoint: vascular mortality from randomization through day 35 | 804 of 8,587 (9.4%) versus 1,016 of 8,600 (11.8%), a 23% odds reduction with 2P<0.00001; successful. | Decisive large direct mortality evidence |
| Antithrombotic Trialists' Collaboration. 2009 | Individual-participant-data meta-analysis of randomized trials | 17,000 | UK Medical Research Council, British Heart Foundation, Cancer Research UK, and European Community Biomed Programme | Serious vascular events | 6.7% versus 8.2% per year, P<0.0001, reproducing fewer clinical events in secondary prevention. | Large confirmatory synthesis |
Receipt — 2 References
All 2 cited sources were verified for existence at the original page (as of 2026-07-24).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-24 · Corrections: none
Cite this verdict
[Chamgap] Aspirin x reduced early vascular mortality in acute myocardial infarction — Evidence Grade A·94. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/heart/aspirin-acute-myocardial-infarction-vascular-mortality/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.